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Introduction
Schizophrenia is a severe psychiatric disorder that has a 
predicted  prevalence  of  about  0.5%  in  the  population 
worldwide [1]. Although it has provided geniuses such as 
the  mathematician  John  Forbes  Nash  and  the  dancer 
Vaslav  Nijinsky,  the  disease  is  debilitating  and  it  is  a 
significant social burden. The direct costs of treatment 
and care associated with schizophrenia in England alone 
for the year 2005 were about two billion pounds. The cost 
for  informal  and  private  care  for  families  was 
£615,000,000,  indicating  a  significant  impact  of  the 
disease on society [2].
Since its description as a distinct syndrome affecting 
teenagers  and  young  adults,  termed  démence  précoce 
(literally  ‘early  dementia’),  by  Bénédict  Morel  in  1853, 
schizophrenia has been associated with a heterogeneity 
of  symptoms  that  have  made  its  identification  proble­
matic. Emile Kraepelin was one of the first to characterize 
it  in  1887,  dividing  it  into  four  categories:  ‘simple’, 
‘paranoid’,  ‘hebephrenic’  and  ‘catatonic’.  Schizophrenia 
got its current name in 1908 from Eugen Bleuler, who 
classified  the  symptoms  into  the  so­called  four  ‘A’s 
categories:  blunted  ‘affect’,  loosening  of  ‘associations’, 
‘ambivalence’ and ‘autism’. Modern diagnosis of schizo­
phrenia  is  based  on  the  World  Health  Organization 
classification  (ICD­10)  [3]  or  the  Diagnostic  and 
Statistical  Manual  of  Mental  Disorders  (DSM­IV)  [4]. 
These  classifications  are  grounded  in  the  classification 
provided  by  Kurt  Schneider  in  1959,  with  no  direct 
correlation  between  symptoms  and  physiological 
evidence of the disease [5]. A revision of the characteristic 
symptoms and classification of schizophrenia is now in 
progress, and DSM­V will be published in 2013. However, 
diagnosis will still rely on the subjective judgment of a 
patient’s behavior and experience, aided by the observed 
response  to  drug  treatment  as  an  additional  indicator. 
The  symptoms  of  schizophrenia  are  classified  in  two 
different categories: positive and negative. Some of the 
most frequently positive symptoms are delusions, halluci­
nations and reality distortions, whereas loss of motiva­
tion, poverty of speech, apathy and reduced social drive 
belong to the negative manifestations of the disease.
Many hypotheses have been formulated to explain the 
symptoms of schizophrenia. Due to the ability of several 
neuroleptic  drugs,  such  as  haloperidol,  to  mitigate 
positive  symptoms,  the  implication  of  deregulation  in 
dopamine transmission was widely studied and led to the 
postulation  of  the  hyperdopaminergic  hypothesis  of 
schizo  phrenia [6]. Meanwhile, studies of use or abuse of 
phenclyclidine  or  ketamine,  which  are  N­methyl­d­
aspar  tate  receptor  antagonists,  revealed  the  possible 
implica  tion  of  glutamatergic  transmission  in  the 
pathology of the disorder [7]. These drugs can produce 
schizophrenic­like  positive  and  negative  symptoms  in 
healthy individuals and severely aggravate the symptoms 
of  patients  with  schizophrenia  [8,9].  More  recently, 
schizophrenia was postulated to be a neurodevelopmental 
disorder.  Deregulation  of  brain  development  in  early 
child  hood and adolescence is thought to lead to struc­
tural  and  functional  disconnectivity  that  causes  the 
symp  toms  of  schizophrenia  [10].  As  for  many  multi­
factorial complex diseases, conceptualization is hampered 
by the confusion between the pathogenesis, the causes of 
the disease, and the symptomatology, with the symptoms 
resulting from the disease. The distinction between the 
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Pathogenesis
Although  environmental  risk  factors  play  a  role  in  the 
progress  of  schizophrenia,  there  seems  to  be  a  strong 
heritable component for the development of the disease, 
as observed in twin studies [11] and in high­incidence 
families [12]. Knowledge of the susceptibility genes could 
improve  the  treatment  of  patients  by  allowing  earlier 
intervention through treatment, increasing the chances 
of alleviating the symptoms or even recovery. To date, 
many genomic studies, such as linkage analysis, genome 
association,  genome­wide  analysis  of  single  nucleotide 
polymorphism and copy number variations, have tried to 
investigate the genetic origin of schizophrenia, without 
clear­cut  results.  Using  the  genetic  information  from 
families with a high incidence for the disease, candidate 
chromosomal regions have been identified [13,14]. Single 
nucleotide  polymorphism  analysis,  which  for  other 
diseases such as Parkinson’s disease or Alzheimer’s disease 
has clearly highlighted interesting candidate genes, has 
shown  ambiguous  results  for  schizophrenia.  Never  the­
less, different gene sets have been highlighted, including 
ERBB4, major histocompatibility complex (MHC) class I 
and  II  [15],  COMT  [16]  and  DISC1  [17],  although  the 
data appear to lack reproducibility. This may be due to 
the  susceptibility  of  these  approaches  to  false­positive 
results.  Additionally,  the  phenotypic  heterogeneity  of 
schizophrenia could also be the result of a heterogeneous 
pathogenotype diluting signals of single interesting genes 
in genome­wide studies.
Molecular symptomatology
In addition to genomic studies, transcriptomic [18] and 
proteomic  [19]  approaches  have  been  used,  producing 
sets of candidate genes that are not necessarily congruent 
with other studies. Moreover, in the analysis of data from 
divergent  sources,  we  must  bear  in  mind  that  medical 
treatment can cause severe differences in protein produc­
tion levels and tissue organization [20]. Cause of death, 
handling and sample preparation must also be taken into 
account. Although it is difficult to name specific genes or 
proteins  that  are  involved  in  the  development  of  the 
disease,  some  biological  functions  seem  to  play  a 
particularly important role, such as certain cell signaling 
pathways, synaptic transmission, energy metabolism with 
a  particular  focus  on  mitochondrial  protein,  and 
oxidative  stress  damage  [21].  Recently,  a  coexpression 
network  analysis  was  performed  by  Torkamani  and 
colleagues  [22]  using  microarray  expression  data  from 
postmortem  brain  samples.  The  study  included  47 
patients with schizophrenia (diagnosis based on DSM­IV 
criteria) and 54 healthy controls, with an age range of 19 
to 81 years. They used the ARACNE algorithm, which is 
an  information  theoretic  approach  [23],  on  the  micro­
array  expression  profiles  to  determine  the  underlying 
regulatory  network  topology  and  identify  regulatory 
modules  therein  using  hierarchical  clustering.  This 
analysis emphasized that schizophrenia might not be the 
result of just a few highly deregulated candidate genes. It 
suggested  that  the  overall  regulatory  structure  in  the 
schizophrenic brain is kept intact, while subtle deregu­
lations  occur  within  certain  identified  regulatory 
modules. Gene ontology enrichment studies relate those 
affected modules to typical neuronal functions. The study 
addressed  not  only  the  differential  gene  regulation 
between cases and controls, but also the developmental 
and  degenerative  nature  of  schizophrenia,  taking  into 
account the age of each subject. Analysis of the data also 
highlighted  modules  that  might  be  differentially 
expressed,  dependent  on  age,  in  healthy  and  diseased 
subjects.
A schizophrenic brain might resemble a juvenile 
brain
Torkamani  and  colleagues  identified  sets  of  genes  that 
showed age­dependent regulation in patients, but not in 
healthy subjects, including genes functionally related to 
chromosome organization, the cell cycle, DNA damage 
repair,  transport  processes,  lipid  metabolism,  neuronal 
regeneration  and  neurogenesis.  Conversely,  the  age­
related downregulation of genes in modules associated 
with developmental processes such as neuronal differen­
tiation,  neurite  outgrowth  and  synaptic  transmission 
appeared  to  be  absent  in  patients  with  schizophrenia. 
These  findings  lend  weight  to  the  neurodevelopmental 
hypothesis  of  schizophrenia.  A  recent  imaging  study 
showed  that  one  of  the  prominent  phenotypical 
properties  of  the  schizophrenic  brain  is  an  abnormal 
development of grey matter [24]. Grey matter density in 
patients  with  schizophrenia  peaks  during  adolescence, 
and then it decreases faster than in healthy individuals. 
The healthy group displays a continuous decrease from 
early adolescence onwards, and this slows down during 
adulthood.  This  difference  reflects  the  progressive 
character  of  the  disease,  and  might  be  related  to  the 
groups of age­dependent genes deregulated in patients. A 
component  of  the  disease  seems  to  be  abnormal 
development of the brain, which is blocked in a juvenile 
stage,  as  suggested  by  the  modules  that  fail  to  be 
downregulated  in  patients  with  schizophrenia.  Among 
the genes involved is the gene encoding dopamine D1 
receptor, which is usually downregulated during aging, 
and is foremost in cortical and caudate regions in normal 
individuals  [25].  Included  in  the  dataset  studied  by 
Torkamani and colleagues was COMT (the gene encoding 
catechol­O­methyl  transferase),  which  is  another  gene 
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implicated in the development of schizophrenia. COMT 
is part of the differentially regulated modules that are age 
independent.  The  hyperactive  state  of  the  dopamine 
system  in  a  patient  with  schizophrenia  resembles  the 
dopamine  hyperactivity  in  the  brain  of  an  adolescent 
[26],  and  it  might  show  how  a  regulatory  feature  that 
might be beneficial during a certain life stage (at least on 
a  population  based  scale)  could  result  in  a  psychiatric 
disease if proper shutdown of the system fails. Unfor  tu­
nately, the dopamine D2 receptor, upon which the dopa­
mine hypothesis of schizophrenia was originally based, 
was not present in the dataset studied by Torkamani and 
colleagues. The glutamate system in the brain of patients 
is also affected. The number of glutamatergic synapses 
peaks during early childhood in healthy individuals, and 
subsequently  decreases  with  rapid  decline  during 
adolescence  [27].  In  the  schizophrenic  brain,  this 
mechanism fails, again indicating that the brain is stuck 
in an adolescent developmental stage.
Conclusions
A major issue today lies in the diagnosis of schizophrenia 
because of its very broad symptomatic range. This is also 
reflected  in  the  outcome  of  genomic  and  proteomic 
studies.  Many  of  the  candidate  genes  that  have  been 
identified  are  shared  with  other  mental  disorders. 
Schizophrenia  might  not  be  a  single  disease  with  a 
distinct  and  clear  pathogenesis,  but  rather  a  sum  of 
different subtle genetic deregulations. The subset of these 
deregulations present in each individual could account 
for the heterogeneity of the observed different psychotic 
phenotypes. Small­scale analyses, such as family studies, 
tend to associate single genetic variations with a disease. 
These  variations  could  be  a  major  risk  factor  for  that 
family, but might not cause the disease when put into 
another genetic background, and this is where large­scale 
analyses come into play. In a sufficiently large dataset, the 
effect  of  emphasizing  single  variations  is  averaged  out 
and allows the analysis of biological pathways instead of 
single genes, as presented in the paper by Torkamani et 
al. When sufficient data become available, quantitative 
compu  tational  systems  biology  could  provide  kinetic 
models  that  aid  in  understanding  the  nature  of  the 
deregulations  present  in  the  pathways  of  the  schizo­
phrenic brain. This would allow the identification of a set 
of network nodes that could be targeted in a combined 
drug  therapy.  A  polypharmacology  approach,  where 
multiple targets are taken into account at the same time, 
could help the network to restore a healthy state.
One  of  the  issues  to  be  addressed  in  schizophrenia 
research  is  the  standardization  of  protocols  and  the 
minimum amount of information required for a study. 
Examples in various fields have been gathered under the 
umbrella of the Minimum Information for Biological and 
Biomedical  Investigations  project  [28].  Especially  in 
schizophrenia  research,  it  is  necessary  to  provide  the 
history of drug treatment, the cause of death and the age 
of a sample, as well as environmental factors that might 
have influenced development of the disease. A rigorous 
statistical approach to the data and its clear declaration 
should also be included. It is also advisable to provide 
general  access  to  the  data  and  analyses  to  enable 
comparisons  between  studies,  interpretation  of  results, 
and meta analyses.
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